Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chimerix Chooses Merck As HIV Partner, Keeps Broad-Spectrum Antiviral

This article was originally published in The Pink Sheet Daily

Executive Summary

The North Carolina-based start-up strikes a global deal for a Phase I HIV drug, which will allow it to fund late-stage trials on another lipid-antiviral conjugate.

Advertisement

Related Content

With A Drug On The Fast Track, Chimerix Aims To Go Public
Deals Of The Week: BioCryst/Presidio, Merck/AiCuris, Kite/National Cancer Institute
Merck Steps Up As AiCuris’ First Development Partner
Deals Of The Week: Merck/Chimerix, Merck/Yamasa, CoDa/Rusnano/Domain
Smallpox Drug Development May Get Boost From FDA

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS074426

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel